The Ministry of Health announced Wednesday that it withdrew the antipyretic and pain reliever Panadol Baby and Infant upon a request from GlaxoSmithKline, the producer of the drug. A mistake was discovered in the dosage rates written on the package of the product which could lead to liver problems, head of the Ministry’s drug registration dept. Rami Behbehani said in statements to KUNA. He asked all physicians not to prescribe Panadol Baby and Infant for the time being until GlaxoSmithKline finalizes revising the dosage info.
Source : KUNA
Leave a Reply